Op-ed proposes state vaccine plants as a backstop if federal injury compensation is overhauled
States could build their own vaccine factories if federal changes undercut the 40-year-old injury compensation program, an op-ed in STAT argues. The changes are described only as under consideration, so the plan is a contingency.
The Scientist · Science desk
Key figures: the op-ed says autism-related claims could produce $100 billion in awards, far above the program's $4 billion balance. Around 10,500 injury claims were awarded compensation from 2006 to 2024, per government data the op-ed cites.
| Figure | Value | Note | Claim |
|---|---|---|---|
| Awards autism claims could produce, per op-ed | $100,000,000,000 | 10 | |
| VICP balance | $4,000,000,000 | 13 | |
| Claims awarded, around | 10,500 claims | 6 |
What happened
- Reporting the op-ed cites suggests Health Secretary Robert F. Kennedy Jr. and an adviser may remove certain vaccines, such as childhood vaccines, from the program, raising manufacturers' legal liability.
- In the author's account of the 1980s, only one US company still made the whooping cough vaccine by 1984, and it had raised its price tenfold.
- MassBiologics, run by UMass Chan Medical School, is the nation's only nonprofit vaccine manufacturer and makes a tetanus and diphtheria vaccine distributed nationwide.
Why it matters
- exposure Makers of the childhood vaccines named in the reporting would face uncapped liability first, so an exit, if one came, would show up there before anywhere else.
- decision State health departments and university systems, the bodies the op-ed assigns to build capacity, face a choice between planning before any federal change and waiting for shortages.
- constraint The op-ed's working example is a single operator, so how much lost private supply states could replace is untested.
The plan depends on changes the administration is only reported to be considering. The op-ed says the administration is "reportedly considering" changes to the Vaccine Injury Compensation Program (VICP) [8], and that it may make autism-related conditions compensable, based on claims the author calls debunked [10]. The author's case for state action, set out in a new paper the op-ed mentions, starts from those possibilities [12].
The strongest evidence in the op-ed is historical. In the 1980s, lawsuits alleged that diphtheria, tetanus and whooping cough vaccines caused severe seizures in children. Researchers later debunked many of those claims, the author writes, but makers still faced significant payouts, raised prices, and in some cases left the market [1]. Congress answered with the VICP, which compensates injured patients and caps makers' liability [3]. The 1980s are one episode, and the link from payouts to exits is the author's reading of it.
The size of the threat rests on a figure that is itself conditional. The author says autism-related claims could produce $100 billion in awards [10]. Awards on that scale would come to 25 times the $4 billion fund balance [13].
A second figure needs its denominator checked. The op-ed cites government data showing more than 5 billion covered doses and around 10,500 compensated claims from 2006 to 2024, and calls that about one individual per million doses [6]. At exactly 5 billion doses, 10,500 awards works out to 2.1 per million [7]. The source says "more than" 5 billion, so the true rate is somewhat lower. Awards are rare on either count.
Massachusetts founded MassBiologics in 1894, and it has made vaccines for smallpox, tetanus, typhoid and pertussis [4]. The op-ed would copy MassBiologics: each state could use its health department or university system to set up production [11].
The op-ed, in the text we reviewed, does not include what a plant costs, how long one takes to build, or who would carry liability for its output. We think the 1980s history supports the worry and MassBiologics supports feasibility at small scale. Neither shows that states could prevent a national shortage, and the argument holds only if the federal changes happen and makers then leave.
What to watch
- Whether HHS formally proposes removing vaccines from the VICP or making autism-related conditions compensable, since the op-ed describes both only as possibilities.
- Whether any manufacturer announces it is leaving a US vaccine line, the step the shortage argument depends on.
- Whether any state health department or university system, MassBiologics included, announces plans to expand production.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence30
- Adoption
- Insufficient
- Hype gap+35
- Incentives
- Insufficient
- Confidence40
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
The op-ed says that in the 1980s a flood of lawsuits alleged diphtheria, tetanus and whooping cough vaccines caused severe seizures in children; researchers belatedly debunked many of the claims, but vaccine makers faced significant payouts, raised prices, and some exited the market.
- [2]
The op-ed says that by 1984 only one company was left producing the whooping cough vaccine in the United States and it had raised its price tenfold.
- [3]
Congress created the VICP, which provides compensation to patients injured by vaccines while capping the legal liability of vaccine makers.
- [4]
Massachusetts created a public drug manufacturer and research lab, MassBiologics, in 1894; it has produced vaccines for smallpox, tetanus, typhoid and pertussis, among other biologic products.
- [5]
MassBiologics, now operated by the UMass Chan Medical School, remains the nation's only nonprofit vaccine manufacturer and currently produces a tetanus and diphtheria vaccine distributed nationwide.
- [6]
Per government data cited in the op-ed, more than 5 billion doses of covered vaccines were distributed in the US between 2006 and 2024, and around 10,500 injury claims were awarded compensation under the VICP, which the op-ed puts at about one individual per 1 million administered doses.
- [7]
At exactly 5 billion doses, 10,500 compensated claims is 2.1 per million doses; because the source says 'more than' 5 billion doses, the true rate is somewhat lower.
- [8]
The op-ed says the Trump administration is reportedly considering changes to the Vaccine Injury Compensation Program, which it says has protected domestic vaccine supply for 40 years.
- [9]
Reporting cited in the op-ed suggests Health Secretary Robert F. Kennedy Jr. and one of his chief advisers may remove certain vaccines, such as the childhood vaccines the administration is trying to make optional under federal recommendations, from the VICP, which would increase legal liability for producers of those vaccines.
- [10]
The op-ed says that, based on debunked claims linking autism to vaccines, the administration may make conditions related to autism compensable injuries under the VICP, and that such claims could produce $100 billion in awards, far above the program's $4 billion balance and approaching 20 times what the fund has paid on all claims to date.
- [11]
The op-ed says each state could use its health department or university system to establish production facilities for vaccines jeopardized by federal policy.
- [12]
The op-ed's author says a new paper explains how state policymakers can step in to directly produce vaccines to prevent shortages.
- [13]
The op-ed's $100 billion potential award figure is 25 times the program's $4 billion balance.
Get this ledger inside ChatGPT. Ask about any of our stories and the answer brings its figure, each claim’s verdict and the sources. Free, no account.
Sources
1 independent publisher whose own reporting we read for this story.
- statnews.comOpinion: How states can resist the potential Trump vaccine shortages
1 article · October 14, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Topics
- Vaccine PolicyFollow
- Public vaccine manufacturingFollow
- Vaccine injury compensationFollow